RIGS/ACT technology to activate T cells from lymph nodes data

NEOP announced preliminary results of the adoptive cellular therapy as an adjunct to RIGS surgery in 30 evaluable patients, 29 of whom had extensive liver disease as well as extrahepatic involvement.

Median survival is at least 15 months, compared to historic values of six months, the company reported at the Raymond James Healthcare Conference in New York. ...